Relay Therapeutics, Inc. (RLAY)

Market Cap	1.64B +143.9%
Revenue (ttm)	15.36M +53.4%
Net Income	-276.48M
EPS	-1.61
Shares Out	178.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,735,639
Open	9.19
Previous Close	9.22
Day's Range	8.84 - 9.41
52-Week Range	1.78 - 9.54
Beta	1.62
Analysts	Strong Buy
Price Target	15.75 (+71.94%)
Earnings Date	Feb 26, 2026

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $15.75, which is an increase of 71.94% from the latest price.

Price Target

$15.75

(71.94% upside)

Analyst Consensus: Strong Buy